Hellmann MD, et al. Efficacy/Safety of Entinostat (ENT) and Pembrolizumab (PEMBRO) in NSCLC Patients Previously Treated with Anti-PD-(L)1 Therapy. IASLC 2018, abstract OA05.01.
Divarasib bij solide tumoren met KRAS G12C-mutatie
nov 2023 | Longoncologie, Maag-darm-leveroncologie